本文關(guān)鍵詞： 浸潤性乳腺癌 miR- 分子亞型　出處：《臨床醫(yī)藥文獻(xiàn)電子雜志》2017年26期 　論文類型：期刊論文

【摘要】：目的觀察乳腺癌組織中miRNA-210的表達(dá)水平,分析其與乳腺癌臨床病理中腫瘤分子亞型的關(guān)系。方法收集本院確診的50例浸潤性乳腺癌患者經(jīng)手術(shù)切除的乳腺癌組織標(biāo)本及正常乳腺組織(距癌腫邊緣5cm),采用實(shí)時(shí)定量RT-RCR(q RT-PCR)法檢測miRNA-210表達(dá)水平,收集對應(yīng)乳腺癌患者的臨床病理資料,分析乳腺癌組織中miRNA-210與腫瘤分子分型的關(guān)系。結(jié)果浸潤性乳腺癌組織中miRNA-210在HER-2高表達(dá)型乳腺癌組織中表達(dá)最高,其次是三陰型乳腺癌,在Luminal B型的兩個(gè)分型中表達(dá)相似,在Luminal A型中表達(dá)最低,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。浸潤性乳腺癌組中miRNA-210表達(dá)與患者年齡、腫瘤大小、組織分級及病理分期等方面的差異無統(tǒng)計(jì)學(xué)意義(P0.05),因此與其他臨床病理參數(shù)無關(guān)。結(jié)論 miRNA-210在乳腺癌組織不同分子分型中表達(dá)水平不同,且與乳腺癌分子分型相關(guān),可以作為乳腺癌分子分型診斷的參考及三陰型乳腺癌治療的新突破。
[Abstract]:Objective to observe the expression of miRNA-210 in breast cancer. To analyze the relationship between tumor molecular subtype and breast cancer clinicopathology methods 50 breast cancer specimens and normal breast tissues (5 cm from the margin of cancer) were collected from 50 patients with invasive breast cancer confirmed in our hospital. The expression of miRNA-210 was detected by real-time quantitative RT-RCR(q RT-PCR. The clinicopathological data of breast cancer patients were collected to analyze the relationship between miRNA-210 and tumor molecular typing in breast cancer tissues. Results the expression of miRNA-210 in invasive breast cancer tissues was the highest in high expression of HER-2 breast cancer, followed by triple negative type breast cancer. The expression of miRNA-210 was similar in the two types of Luminal B, and the lowest in type A of Luminal, and the difference was statistically significant (P 0.05). The expression of miRNA-210 was correlated with the age and tumor size of the patients with invasive breast cancer. There was no significant difference in histological grade and pathological stage, so it was not related to other clinicopathological parameters. Conclusion the expression level of miRNA-210 in different molecular classification of breast cancer is different, and it is related to the molecular classification of breast cancer. It can be used as a reference for molecular typing diagnosis of breast cancer and a new breakthrough in the treatment of triple negative breast cancer.
【作者單位】： 山東青島大學(xué)醫(yī)學(xué)院附屬醫(yī)院乳腺外科;山東青島大學(xué)醫(yī)學(xué)院生物化學(xué)與分子生物學(xué)教研室;
【分類號】：R737.9
，

本文編號：1511269